» Articles » PMID: 20484295

Uric Acid Increases Fibronectin Synthesis Through Upregulation of Lysyl Oxidase Expression in Rat Renal Tubular Epithelial Cells

Overview
Specialties Nephrology
Physiology
Date 2010 May 21
PMID 20484295
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Urate is produced as the major end product of purine metabolism. In the last decade, the incidence of hyperuricemia increased markedly, and similar trends in the epidemiology of metabolic syndrome have been observed. Hyperuricemia is associated with renal disease, and recent studies have reported that mild hyperuricemia results in hypertension, intrarenal vascular disease, and renal injury. This has led to the hypothesis that uric acid may contribute to renal fibrosis and progressive renal disease. Our purpose was to investigate the relationship between uric acid and renal tubular injury. We applied the method of intraperitoneal injection of uric acid to generate the hyperuricemic mouse model. Compared with the saline injection group, the expression of lysyl oxidase (LOX) and fibronectin in kidneys was increased significantly in hyperuricemic groups. In vitro, uric acid significantly induced NRK-52E cells to express the ECM marker fibronectin, as well as LOX, which plays a pivotal role in ECM maturation, in a time- and dose-dependent manner. Upregulation of the urate transporter URAT1, which is located in the apical membrane of proximal tubules, sensitized the uric acid-induced fibronectin and LOX induction, while both knocking down URAT1 expression in tubular epithelial cells by RNA interference and inhibiting URAT1 function pharmacologically attenuated LOX and fibronectin expression. Furthermore, knockdown of LOX expression by a small interfering RNA strategy led to a decrease in fibronectin abundance induced by uric acid treatment. In addition, evidence of a uric acid-induced activation of the NF-kappaB signaling cascade was observed. Our findings highlight a need for carefully reevaluating our previous view on the pathological roles of hyperuricemia in the kidney and nephropathy induced by uric acid in clinical practice.

Citing Articles

Contribution and expression of renal drug transporters in renal cell carcinoma.

Zuo Y, Li T, Yang S, Chen X, Tao X, Dong D Front Pharmacol. 2025; 15:1466877.

PMID: 40034145 PMC: 11873565. DOI: 10.3389/fphar.2024.1466877.


Models of gouty nephropathy: exploring disease mechanisms and identifying potential therapeutic targets.

Wang L, Zhang X, Shen J, Wei Y, Zhao T, Xiao N Front Med (Lausanne). 2024; 11:1305431.

PMID: 38487029 PMC: 10937455. DOI: 10.3389/fmed.2024.1305431.


The correlation between serum uric acid and diabetic kidney disease in type 1 diabetes patients in Anhui, China.

Jiang J, Zhou X, Lan L, Ren W BMC Nephrol. 2023; 24(1):252.

PMID: 37612612 PMC: 10463645. DOI: 10.1186/s12882-023-03302-2.


The correlation between serum uric acid and diabetic kidney disease in adult-onset type 1 diabetes patients in China.

Jiang J, Zhou X, Lan L, Weng J, Ren W Acta Diabetol. 2023; 60(9):1231-1239.

PMID: 37264251 PMC: 10359385. DOI: 10.1007/s00592-023-02119-7.


Asymptomatic hyperuricaemia in chronic kidney disease: mechanisms and clinical implications.

Anders H, Li Q, Steiger S Clin Kidney J. 2023; 16(6):928-938.

PMID: 37261000 PMC: 10229286. DOI: 10.1093/ckj/sfad006.